<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01281501</url>
  </required_header>
  <id_info>
    <org_study_id>619/2010</org_study_id>
    <nct_id>NCT01281501</nct_id>
  </id_info>
  <brief_title>Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole</brief_title>
  <official_title>A Randomized, Controlled Trial of Adding Intravenous Pantoprazole to Conventional Treatment for the Immediate Relief of Dyspeptic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immediate synergistic effect on the relief of
      severe acid-related dyspeptic pain by adding intravenous pantoprazole to the combination of
      oral antacid and antispasmodic agent (the conventional treatment).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acid-related dyspepsia is common among the population. Number of these patients may have so
      severe symptoms that can lead them to the emergency department. Mixtures of antacid and
      antispasmodic were widely used over decades to relieve this acute pain with moderate, yet
      questionable, improvement in pain score. Proton pump inhibitors (PPIs), the novel
      acid-lowering agents, are undoubtedly effective to reduce acid secretion and control
      dyspeptic symptoms in short-term and long-term duration. To our knowledge, no previous study
      was conducted to evaluate the efficacy of such agents on immediate pain relief in patients
      with severe dyspeptic symptoms in emergency care. Clinically, they are frequently used to
      treat this circumstance in an unofficial manner since intravenous proton pump inhibitor alone
      is not yet considered as a well-approved indication to alleviate such condition.
      Pantoprazole, a proton pump inhibitor, reaches its peak serum concentration within one hour
      and its acid-lowering effect occurred within first hour following a single intravenous
      infusion. Thus, it theoretically has rapid onset and prolonged action on acid reduction. Our
      primary aim of the study is to evaluate the immediate effect of intravenous pantoprazole in
      addition to the combination of oral antacid and antispasmodic agent (the conventional
      regimen) on the relief of severe acid-related dyspeptic pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scores on the 100-millimeter Visual Analog Scale (VAS) at 1 Hour After Treatment</measure>
    <time_frame>1 hour after treatment</time_frame>
    <description>Post-treatment VAS will be consecutively measured every 15 minutes until 1 hour after treatment. Minimal and maximal VAS score of every measurement is 0 to 100 millimeters. VAS scores at 1 hour after treatment were the primary outcome measurement. The patients who had &lt;50% decrement between pre- and 1-hour post-treatment VAS or post-treatment scores &gt; 40 millimeters were defined as &quot;Non-responders&quot;(worse outcome). In the same way, those who had ≥ 50% decrement between pre- and 1-hour post-treatment VAS and post-treatment scores≤ 40 millimeters were defined as &quot;Responders&quot; (good outcome).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in the Predefined &quot;Responders&quot;</measure>
    <time_frame>pretreatment and 1 hour after treatment</time_frame>
    <description>&quot;Responders&quot; define the participants who have ≥ 50% decrease in post-treatment pain scores compared with the pre-treatment evaluation and also have the post-treatment scores ≤ 40 at the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in the Predefined &quot;Non-responders&quot;</measure>
    <time_frame>pretreatment and 1 hour after treatment</time_frame>
    <description>&quot;Non-responders&quot; defined the participants who had &lt; 50% decrease in post-treatment VAS compared with pre-treatment evaluation or post-treatment scores &gt; 40 at the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Effect</measure>
    <time_frame>1 hour after treatment</time_frame>
    <description>The adverse effects include blurred vision, dry mouth, dizziness, headache, palpitation and diarrhea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Have Overall Satisfaction on the Treatment</measure>
    <time_frame>1 hour after treatment</time_frame>
    <description>The satisfaction will be assessed by a simple, self-reported yes/no question.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Dyspepsia</condition>
  <condition>Emergency</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>10 ml of 0.9% sodium chloride solution</description>
    <arm_group_label>Conventional</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>80 mg of intravenous pantoprazole</description>
    <arm_group_label>Pantoprazole</arm_group_label>
    <other_name>Controloc (Protonix)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral antacid</intervention_name>
    <description>30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)</description>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_label>Pantoprazole</arm_group_label>
    <other_name>Antacid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyoscine butylbromide</intervention_name>
    <description>20 mg of intravenous hyoscine butylbromide</description>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_label>Pantoprazole</arm_group_label>
    <other_name>Buscopan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of acid-related dyspepsia

          -  age 15 to 50 years

        Exclusion Criteria:

          -  pre-treatment 100-millimeter linear Visual Analog Scale (100-mm VAS) pain scores less
             than 5.0

          -  known cases of malignancies or terminal illnesses

          -  known cases of major medical problems

          -  allergic to studied drugs

          -  contraindicated to hyoscine butylbromide (glaucoma, myasthenia gravis, paralytic
             ileus, pyloric stenosis, prostatic enlargement, porphyria)

          -  received acid antisecretory agents (proton pump inhibitors or histamine-2 receptor
             antagonists), antispasmodic agents, alcoholic consumption, nonsteroidal
             anti-inflammatory drugs, aspirin and steroids within 5 days or oral antacids within 4
             hours prior to the visit

          -  receiving clopidogrel, statins, iron therapies, warfarins, antiretroviral agents,
             which may have serious drug interaction with the proton pump inhibitors

          -  receiving drugs that have strong anticholinergic activities (e.g. acetylcholinesterase
             inhibitors for Parkinson's or Alzheimer diseases, antihistamines, antispasmodic
             agents, antipsychotics, skeletal muscle relaxants, tricyclic antidepressants) or
             decongestants, which may have serious drug interaction with hyoscine butylbromide

          -  suspected other alternative diagnoses (e.g. gut obstruction, biliary colic,
             pancreatitis, hepatitis or localized hepatobiliary infections, etc.)

          -  pregnancy or breast-feeding participants

          -  did not comprehend the Visual Analog Scale (VAS) evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khrongwong Musikatavorn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emergency Medicine Unit, King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Patumwan</city>
        <state>Bangkok</state>
        <zip>11130</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <results_reference>
    <citation>Musikatavorn K, Tansangngam P, Lumlertgul S, Komindr A. A randomized controlled trial of adding intravenous pantoprazole to conventional treatment for the immediate relief of dyspeptic pain. Am J Emerg Med. 2012 Nov;30(9):1737-42. doi: 10.1016/j.ajem.2012.02.001. Epub 2012 Mar 29.</citation>
    <PMID>22463973</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2011</study_first_submitted>
  <study_first_submitted_qc>January 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2011</study_first_posted>
  <results_first_submitted>April 8, 2012</results_first_submitted>
  <results_first_submitted_qc>June 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 27, 2012</results_first_posted>
  <last_update_submitted>September 9, 2013</last_update_submitted>
  <last_update_submitted_qc>September 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Khrongwong Musikatavorn, MD.</investigator_full_name>
    <investigator_title>Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital.</investigator_title>
  </responsible_party>
  <keyword>Dyspepsia</keyword>
  <keyword>Emergency treatment</keyword>
  <keyword>Pantoprazole</keyword>
  <keyword>Antacid</keyword>
  <keyword>Pain measurement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Anti-Ulcer Agents</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
    <mesh_term>Antacids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment began in January, 1 2011 and finished at the end October, 31 2011 in the Emergency Department of King Chulalongkorn Memorial Hospital</recruitment_details>
      <pre_assignment_details>We analyzed the data for all enrolled patients with the intention-to-treat principles.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Conventional</title>
          <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline</description>
        </group>
        <group group_id="P2">
          <title>Pantoprazole</title>
          <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Conventional</title>
          <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline</description>
        </group>
        <group group_id="B2">
          <title>Pantoprazole</title>
          <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="87"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.8" spread="8.1"/>
                    <measurement group_id="B2" value="29.4" spread="9.2"/>
                    <measurement group_id="B3" value="29.6" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pretreatment 100-millimeter visual analog scale (VAS) scores</title>
          <description>Self-marked pain scores on the 100-millimeter VAS lines were assessed by the patients before treatment. The minimal and maximal scores were between 0-100 millimeters. Good responders (good outcome) defined those had ≥ 50% decreases in post-treatment VAS compared with the pre-treatment evaluation and post-treatment scores ≤ 40 millimeters at the end of the study. Non-responders (worse outcome) defined those who had &lt;50% decreases in post-treatment VAS compared with the pre-treatment evaluation or post-treatment scores &gt; 40 millimeters at the end of the study.</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="13"/>
                    <measurement group_id="B2" value="64" spread="16"/>
                    <measurement group_id="B3" value="64" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Scores on the 100-millimeter Visual Analog Scale (VAS) at 1 Hour After Treatment</title>
        <description>Post-treatment VAS will be consecutively measured every 15 minutes until 1 hour after treatment. Minimal and maximal VAS score of every measurement is 0 to 100 millimeters. VAS scores at 1 hour after treatment were the primary outcome measurement. The patients who had &lt;50% decrement between pre- and 1-hour post-treatment VAS or post-treatment scores &gt; 40 millimeters were defined as “Non-responders”(worse outcome). In the same way, those who had ≥ 50% decrement between pre- and 1-hour post-treatment VAS and post-treatment scores≤ 40 millimeters were defined as “Responders” (good outcome).</description>
        <time_frame>1 hour after treatment</time_frame>
        <population>All enrolled patients were analyzed with the intention-to-treat principles.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional</title>
            <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline</description>
          </group>
          <group group_id="O2">
            <title>Pantoprazole</title>
            <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores on the 100-millimeter Visual Analog Scale (VAS) at 1 Hour After Treatment</title>
          <description>Post-treatment VAS will be consecutively measured every 15 minutes until 1 hour after treatment. Minimal and maximal VAS score of every measurement is 0 to 100 millimeters. VAS scores at 1 hour after treatment were the primary outcome measurement. The patients who had &lt;50% decrement between pre- and 1-hour post-treatment VAS or post-treatment scores &gt; 40 millimeters were defined as “Non-responders”(worse outcome). In the same way, those who had ≥ 50% decrement between pre- and 1-hour post-treatment VAS and post-treatment scores≤ 40 millimeters were defined as “Responders” (good outcome).</description>
          <population>All enrolled patients were analyzed with the intention-to-treat principles.</population>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" spread="24"/>
                    <measurement group_id="O2" value="19" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is that the treatment with pantoprazole arm is not different in immediate relief of acute, severe dyspeptic pain compared with conventional arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.7</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in the Predefined &quot;Responders&quot;</title>
        <description>&quot;Responders&quot; define the participants who have ≥ 50% decrease in post-treatment pain scores compared with the pre-treatment evaluation and also have the post-treatment scores ≤ 40 at the end of the study.</description>
        <time_frame>pretreatment and 1 hour after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional</title>
            <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline</description>
          </group>
          <group group_id="O2">
            <title>Pantoprazole</title>
            <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in the Predefined &quot;Responders&quot;</title>
          <description>&quot;Responders&quot; define the participants who have ≥ 50% decrease in post-treatment pain scores compared with the pre-treatment evaluation and also have the post-treatment scores ≤ 40 at the end of the study.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in the Predefined &quot;Non-responders&quot;</title>
        <description>“Non-responders” defined the participants who had &lt; 50% decrease in post-treatment VAS compared with pre-treatment evaluation or post-treatment scores &gt; 40 at the end of the study.</description>
        <time_frame>pretreatment and 1 hour after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional</title>
            <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline</description>
          </group>
          <group group_id="O2">
            <title>Pantoprazole</title>
            <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in the Predefined &quot;Non-responders&quot;</title>
          <description>“Non-responders” defined the participants who had &lt; 50% decrease in post-treatment VAS compared with pre-treatment evaluation or post-treatment scores &gt; 40 at the end of the study.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Effect</title>
        <description>The adverse effects include blurred vision, dry mouth, dizziness, headache, palpitation and diarrhea.</description>
        <time_frame>1 hour after treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Have Overall Satisfaction on the Treatment</title>
        <description>The satisfaction will be assessed by a simple, self-reported yes/no question.</description>
        <time_frame>1 hour after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional</title>
            <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline</description>
          </group>
          <group group_id="O2">
            <title>Pantoprazole</title>
            <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Have Overall Satisfaction on the Treatment</title>
          <description>The satisfaction will be assessed by a simple, self-reported yes/no question.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 hour</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Conventional</title>
          <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline</description>
        </group>
        <group group_id="E2">
          <title>Pantoprazole</title>
          <description>Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>palpitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>transient blurred vision</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="44"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="44"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>1. This was a small, single-centered study. 2. Exaggerated self-evaluation of the patients' pain score and the physician’s expectation of a “good outcome” may also have biased the report. 3. The short-term recurrence of the pain was not studied.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Khrongwong Musikatavorn, MD</name_or_title>
      <organization>Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital.</organization>
      <phone>+662-256-4000 ext 4553-5</phone>
      <email>kmusikatavorn@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

